

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT


Complete if Known

Application Number	10/801,951
Filing Date	March 17, 2004
First Named Inventor	William F. DeGrado
Art Unit	1615
Examiner Name	Chong, Yong Soo
Attorney Docket Number	1694.0630003/JMC/AES

[illegible]

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Country Code ² Number ³ Kind Code ³ (if known)		
YC	FP1	JP 63-108019 A	05/12/1988	Takiron Co. Ltd.
I	FP2	JP 2003-165805 A	06/10/2003	Mitsubishi Rayon Co. Ltd.
I	FP3	JP 2004-168802 A	06/17/2004	Sawaguchi Takashi <i>et al.</i>
I	FP4	JP 2004-323688 A	11/18/2004	Mitsubishi Rayon Co. Ltd.


543783 1.DOC

Examiner Signature		Date Considered	3/13/07
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.




PTO/SB/08B (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/801,951
				Filing Date	March 17, 2004
				First Named Inventor	William F. DeGrado
				Art Unit	1615
				Examiner Name	Chong, Yong Soo
				Attorney Docket Number	1694.0630003/JMC/AES
Sheet	1	of	1		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published, etc.	T ²
YC	NPL1	Patent Abstracts of Japan, English language abstract of JP 63-108019 A.	
	NPL2	Patent Abstracts of Japan, English language abstract of JP 2003-165805 A.	
	NPL3	Patent Abstracts of Japan, English language abstract of JP 2004-168802 A.	
	NPL4	Patent Abstracts of Japan, English language abstract of JP 2004-323688 A.	
	NPL5	Copy of Office Action for U.S. Application No. 10/471,028, DeGrado, W., et al., filed May 11, 2004 (35 U.S.C. § 371(c) date), mailed October 11, 2005	
	NPL6	Copy of final Office Action for U.S. Application No. 10/471,028, DeGrado, W., et al., filed May 11, 2004 (35 U.S.C. § 371(c) date), mailed May 8, 2006	
	NPL7	Co-pending U.S. Application No. 11/361,050, DeGrado, W., et al., filed February 24, 2006 (NOT PUBLISHED)	

543803_1.DOC

Examiner Signature		Date Considered	3/13/07
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible]

450471 1.DOC

Examiner Signature	<i>[Signature]</i>	Date Considered	3/13/07
-----------------------	--------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/801,951
				Filing Date	March 17, 2004
				First Named Inventor	William F. DeGrado
				Art Unit	1615
				Examiner Name	To Be Assigned
Sheet	1	of	1	Attorney Docket Number	1694.0630003/JMC/AES

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published, etc.	T ²
YK	BB8	Dialog File 351, Accession No. 11931138, English language abstract of WO 98/17625 A1 (Document AU2 on accompanying Form PTO/SB/08A)	


455008_1.DOC

Examiner Signature		Date Considered	3/12/07
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/801,951		
		Filing Date	March 17, 2004		
		First Named Inventor	William F. DeGrado		
		Art Unit	1615		
		Examiner Name	To be assigned		
Sheet	1	of	2	Attorney Docket Number	1694.0630003/JMC/AES

U.S. PATENT DOCUMENTS					
Examiner Initials ⁵	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
✓	AA1	3,829,563	08/13/1974	Barry <i>et al.</i>	
	AB1	4,343,788	08/10/1982	Mustacich <i>et al.</i>	
	AC1	4,392,848	07/12/1983	Lucas <i>et al.</i>	
	AD1	5,071,648	12/10/1991	Rosenblatt	
	AE1	5,847,047	12/08/1998	Haynie	
	AF1	5,856,245	01/05/1999	Caldwell <i>et al.</i>	
	AG1	5,874,164	02/23/1999	Caldwell	
	AH1	5,912,116	06/15/1999	Caldwell	
	AI1	6,034,129	03/07/2000	Mandeville III <i>et al.</i>	
	AJ1	6,040,251	03/21/2000	Caldwell	
	AK1	6,083,602	07/04/2000	Caldwell <i>et al.</i>	
	AL1	2004/0102941	05/27/2004	Lopez <i>et al.</i>	
	AM1	2004/0107056	06/03/2004	Doerksen <i>et al.</i>	
	AN1	2004/0185257	09/23/2004	DeGrado <i>et al.</i>	
	AO1	2004/0202639	10/14/2004	DeGrado <i>et al.</i>	
	AP				
	AQ				
	AR				
	AS				

FOREIGN PATENT DOCUMENTS						
Examiner Initials ⁵	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, columns, lines, where relevant passages or figures appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁴ (if known)				
✓	AT1	WO 90/04401	05/03/1990	Lehigh University		
	AU1	WO 95/00547	01/05/1995	E.I. DuPont De Nemours & Co.		
	AV1	WO 97/29160	08/14/1997	Surface Solutions Labs., Inc.		
	AW1	WO 97/49413	12/31/1997	Geltex Pharmaceuticals, Inc.		
	AX1	WO 02/072007	09/19/2002	The Univ. of Pennsylvania		
	AY1	WO 02/100295	12/19/2002	The Univ. of Pennsylvania		

334136_1.DOC

Examiner Signature		Date Considered	3/13/07
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/801,951
				Filing Date	March 17, 2004
				First Named Inventor	William F. DeGrado
				Art Unit	1615
				Examiner Name	To be assigned
Sheet	2	of	2	Attorney Docket Number	1694.0630003/JMC/AES

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA				
	AB				
	AC				
	AD				
	AE				
	AF				
	AG				
	AH				
	AI				
	AJ				
	AK				
	AL				
	AM				
	AN				
	AO				
	AP				
	AQ				
	AR				
	AS				


FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² Number ³ Kind Code ⁴ (if known)				
✓	AT2	WO 04/082634	09/30/2004	DeGrado et al.		
	AU					
	AV					
	AW					
	AX					
	AY					

Examiner Signature		Date Considered	3/13/07
--------------------	---	-----------------	---------

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
		Application Number	10/801,951
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	March 17, 2004
		First Named Inventor	William F. DeGrado
		Art Unit	1615
		Examiner Name	To be assigned
		Attorney Docket Number	1694.0630003/JMC/AES
Sheet	1	of	8

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published, etc.	T ²
YC	BA1	Andersen, J.H., <i>et al.</i> , "Lactoferrin and cyclic lactoferricin inhibit the entry of human cytomegalovirus into human fibroblasts," <i>Antiviral Res.</i> 51:141-149, Elsevier (2001)	
	BB1	Barany, G., <i>et al.</i> , "Solid-phase peptide synthesis: a silver anniversary report," <i>Int. J. Pept. Protein Res.</i> 30:705-739, Munksgaard International Publishers (1987)	
	BC1	Barron, A.E., and Zuckerman, R.N., "Bioinspired polymeric materials: in-between proteins and plastics," <i>Curr. Opin. Chem. Biol.</i> 3:681-687, Current Biology Ltd. (1999)	
	BD1	Bastian, A., and Schäfer, H., "Human α -defensin 1 (HNP-1) inhibits adenoviral infection in vitro," <i>Regul. Pept.</i> 101:157-161, Elsevier (2001)	
	BE1	Belaid, A., <i>et al.</i> , "In Vitro Antiviral Activity of Dermaseptins Against Herpes Simplex Virus Type 1," <i>J. Med. Virol.</i> 66:229-234, Wiley-Liss (February 2002)	
	BF1	Bjørnholm, T., <i>et al.</i> , "Self-Assembly of Regioregular, Amphiphilic Polythiophenes into Highly Ordered π -Stacked Conjugated Polymer Thin Films and Nanocircuits," <i>J. Am. Chem. Soc.</i> 120:7643-7644, American Chemical Society (1998)	
	BG1	Boman, H.G., "Innate immunity and the normal microflora," <i>Immunol. Rev.</i> 173:5-16, Munksgaard International Publishers (2000)	
	BH1	Boman, H.G., <i>et al.</i> , "Cell-free immunity in Cecropia. A model system for antibacterial proteins," <i>Eur. J. Biochem.</i> 201:23-31, Blackwell Science Ltd. (1991)	
	BI1	Bradley, J.S., and Scheld, W.M., "The Challenge of Penicillin-Resistant <i>Streptococcus pneumoniae</i> Meningitis: Current Antibiotic Therapy in the 1990s," <i>Clin. Infect. Dis.</i> 24 (Suppl. 2):S213-221, University of Chicago Press (1997)	
	BJ1	Broekaert, W.F., <i>et al.</i> , "An automated quantitative assay for fungal growth inhibition," <i>FEMS Microbiol. Lett.</i> 69:55-60, Elsevier (1990)	

334148_1.DOC

Examiner Signature		Date Considered	3/17/07
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.93. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/801,951
				Filing Date	March 17, 2004
				First Named Inventor	William F. DeGrado
				Art Unit	1615
				Examiner Name	To be assigned
Sheet	2	of	8	Attorney Docket Number	1694.0630003/JMC/AES

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published, etc.	T ²
YC	BA2	Butler, J.C., <i>et al.</i> , "The Continued Emergence of Drug-Resistant <i>Streptococcus pneumoniae</i> in the United States: An Update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System," <i>J. Infect. Dis.</i> 174:986-993, University of Chicago Press (1996)	
	BB2	Chen, J., <i>et al.</i> , "Development of Protegrins for the Treatment and Prevention of Oral Mucositis: Structure-Activity Relationships of Synthetic Protegrin Analogues," <i>Biopolymers</i> 55:88-98, Wiley Interscience (2000)	
	BC2	Cole, A.M., <i>et al.</i> , "Retrocyclin: A primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1," <i>Proc. Natl. Acad. Sci USA</i> 99:1813-1818, National Academy of Sciences (February 2002)	
	BD2	Debono, M., and Gordee, R.S., "Antibiotics that Inhibit Fungal Cell Wall Development," <i>Annu. Rev. Microbiol.</i> 48:471-497, Annual Reviews (1994)	
	BE2	DeGrado, W.F., "Design of Peptides and Proteins," in <i>Advances in Protein Chemistry, Volume 39</i> , Anfinsen, C.B., <i>et al.</i> , eds., Academic Press, Inc., San Diego, CA, pp. 51-124 (1988)	
	BF2	DeGrado, W.F., <i>et al.</i> , "Design, Synthesis, and Characterization of a Cytotoxic Peptide with Melittin-Like Activity," <i>J. Amer. Chem. Soc.</i> 103:679-681, American Chemical Society (1981)	
	BG2	DeGrado, W.F., <i>et al.</i> , "Kinetics and Mechanism of Hemolysis Induced by Melittin and by a Synthetic Melittin Analogue," <i>Biophys. J.</i> 37:329-338, Rockefeller University Press (1982)	
	BH2	DeLucca, A.J., and Walsh, T.J., "Antifungal Peptides: Novel Therapeutic Compounds against Emerging Pathogens," <i>Antimicrob. Agents Chemother.</i> 43:1-11, American Society for Microbiology (1999)	
	BI2	Dempsey, C.E., "The actions of melittin on membranes," <i>Biochim. Biophys. Acta</i> 1031:143-161, Elsevier (1990)	
	BJ2	Diness, V., and Østergaard, P.B., "Neutralization of a Low Molecular Weight Heparin (LHN-1) and Conventional Heparin by Protamine Sulfate in Rats," <i>Thromb. Haemost.</i> 56:318-322, Schattauer (1986)	

Examiner Signature		Date Considered	3/18/07
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/801,951
				Filing Date	March 17, 2004
				First Named Inventor	William F. DeGrado
				Art Unit	1615
				Examiner Name	To be assigned
Sheet	3	of	8	Attorney Docket Number	1694.0630003/JMC/AES

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published, etc.	T ²
✓	BA3	Edwards, J.R., <i>et al.</i> , "In Vitro Antibacterial Activity of SM-7338, a Carbapenem Antibiotic with Stability to Dehydropeptidase I," <i>Antimicrob. Agents Chemother.</i> 33:215-222, American Society for Microbiology (1989)	
	BB3	Egal, M., <i>et al.</i> , "Antiviral effects of synthetic membrane-active peptides on Herpes Simplex Virus, Type 1," <i>Int. J. Antimicrob. Agents</i> 13:57-60, Elsevier (1999)	
	BC3	Ganz, T., <i>et al.</i> , "Defensins," <i>Eur. J. Haematol.</i> 44:1-8, Munksgaard (1990)	
	BD3	Ganz, T., <i>et al.</i> , "Defensins. Natural Peptide Antibiotics of Human Neutrophils," <i>J. Clin. Invest.</i> 76:1427-1435, American Society for Clinical Investigation (1985)	
	BE3	Gazit, E., <i>et al.</i> , "Interaction of the Mammalian Antibacterial Peptide Cecropin P1 with Phospholipid Vesicles," <i>Biochemistry</i> 34:11479-11488, American Chemical Society (1995)	
	BF3	Gellman, S.H., "Foldamers: A Manifesto," <i>Acc. Chem. Res.</i> 31:173-180, American Chemical Society (1998)	
	BG3	Gennaro, R., and Zanetti, M., "Structural Features and Biological Activities of the Cathelicidin-Derived Antimicrobial Peptides," <i>Biopolymers</i> 55:31-49, Wiley Interscience (2000)	
	BH3	Hamuro, Y., <i>et al.</i> , "De Novo Design of Antibacterial β -Peptides," <i>J. Am. Chem. Soc.</i> 121:12200-12201, American Chemical Society (1999)	
	BI3	Hamuro, Y., <i>et al.</i> , "Novel Folding Patterns in a Family of Oligoanthranilamides: Non-Peptide Oligomers That Form Extended Helical Secondary Structures," <i>J. Am. Chem. Soc.</i> 119:10587-10593, American Chemical Society (1997)	
	BJ3	Hancock, R.E.W., and Lehrer, R., "Cationic peptides: a new source of antibiotics," <i>Trends Biotechnol.</i> 16:82-88, Elsevier Science Publishers B.V. (1998)	

Examiner Signature		Date Considered	3/17/07
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/801,951
				Filing Date	March 17, 2004
				First Named Inventor	William F. DeGrado
				Art Unit	1615
				Examiner Name	To be assigned
Sheet	4	of	8	Attorney Docket Number	1694.0630003/JMC/AES

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published, etc.	T ²
✓	BA4	Haynie, S.L., <i>et al.</i> , "Antimicrobial Activities of Amphiphilic Peptides Covalently Bonded to a Water-Insoluble Resin," <i>Antimicrob. Agents Chemother.</i> 39:301-307, American Society For Microbiology (1995)	
	BB4	Hiramatsu, K., <i>et al.</i> , "Methicillin-resistant <i>Staphylococcus aureus</i> clinical strain with reduced vancomycin susceptibility," <i>J. Antimicrob. Chemother.</i> 40:135-136, Oxford University Press (1997)	
	BC4	Hirsh, J., and Levine, M.N., "Low Molecular Weight Heparin," <i>Blood</i> 79:1-17, American Society of Hematology (1992)	
	BD4	Javadpour, M.M., <i>et al.</i> , "De Novo Antimicrobial Peptides with Low Mammalian Cell Toxicity," <i>J. Med. Chem.</i> 39:3107-3113, American Chemical Society (1996)	
	BE4	Kandrotas, R.J., "Heparin Pharmacokinetics and Pharmacodynamics," <i>Clin. Pharmacokinet.</i> 22:359-374, Adis Intrnational Ltd. (1992)	
	BF4	Landon, C., <i>et al.</i> , "Solution structure of drosomycin, the first inducible antifungal protein from insects," <i>Protein Sci.</i> 6:1878-1884, Cambridge University Press (1997)	
	BG4	Liu, D. <i>et al.</i> , "Nontoxic Membrane-Active Antimicrobial Arylamide Oligomers," <i>Angew. Chem. Int. Ed. Engl.</i> 43:1158-1162, Verlag Chemie (February 2004)	
	BH4	Liu, D., and DeGrado, W.F., "De Novo Design, Synthesis, and Characterization of Antimicrobial β -Peptides," <i>J. Amer. Chem. Soc.</i> 123:7553-7559, American Chemical Society (2001)	
	BI4	Lyytikäinen, O., <i>et al.</i> , "Outbreak caused by two multi-resistant <i>Acinetobacter baumannii</i> clones in a burns unit: emergence of resistance to imipenem," <i>J. Hosp. Infect.</i> 31:41-54, W.B. Saunders (1995)	
	BJ4	Maloy, W.L., and Kari, U.P., "Structure-Activity Studies on Magainins and Other Host Defense Peptides," <i>Biopolymers</i> 37:105-122, Wiley (1995)	

Examiner Signature		Date Considered	3/13/07
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/801,951
				Filing Date	March 17, 2004
				First Named Inventor	William F. DeGrado
				Art Unit	1615
				Examiner Name	To be assigned
Sheet	5	of	8	Attorney Docket Number	1694.0630003/JMC/AES

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published, etc.	T ²
YC	BA5	Margel, S., <i>et al.</i> , "Peptide, protein, and cellular interactions with self-assembled monolayer model surfaces," <i>J. Biomed. Mater. Res.</i> 27:1463-1476, Wiley Interscience (1993)	
	BB5	Merrifield, E.L., <i>et al.</i> , "D-Enantiomers of 15-residue cecropin A-melittin hybrids," <i>Int. J. Pept. Protein Res.</i> 46:214-220, Munksgaard International Publishers (1995)	
	BC5	Merrifield, R.B., <i>et al.</i> , "Design and synthesis of antimicrobial peptides," <i>Ciba Found. Symp.</i> 186:5-26, Wiley (1994)	
	BD5	Merrifield, R.B., <i>et al.</i> , "Retro and retroenantio analogs of cecropin-melittin hybrids," <i>Proc. Natl. Acad. Sci. USA</i> 92:3449-3453, National Academy of Sciences (1995)	
	BE5	Montecalvo, M.A., <i>et al.</i> , "Outbreak of Vancomycin-, Ampicillin-, and Aminoglycoside-Resistant <i>Enterococcus faecium</i> Bacteremia in an Adult Oncology Unit," <i>Antimicro. Agents Chemother.</i> 38:1363-1367, American Society for Microbiology (1994)	
	BF5	Oren, Z., and Shai, Y., "Mode of Action of Linear Amphipathic α -Helical Antimicrobial Peptides," <i>Biopolymers</i> 47:451-463, Wiley Interscience (1998)	
	BG5	Peggion, E., <i>et al.</i> , "Conformation and Interactions of Bioactive Peptides from Insect Venoms: The Bombolitins," <i>Biopolymers</i> 43:419-431, Wiley Interscience (1997)	
	BH5	Porter, E.A., <i>et al.</i> , "Antibiotics: Non-haemolytic β -amino-acid oligomers," <i>Nature</i> 404:565, Nature Publishing Group (2000)	
	BI5	Pouny, Y., <i>et al.</i> , "Interaction of Antimicrobial Dermaseptin and Its Fluorescently Labeled Analogs with Phospholipid Membranes," <i>Biochemistry</i> 31:12416-12423, American Chemical Society (1992)	
	BJ5	Samson, N., <i>et al.</i> , "Relationships Between Synthesis and Mechanical Properties of New Polyurea Materials," <i>J. Appl. Polym. Sci.</i> 65:2265-2280, Wiley (1997)	

Examiner Signature		Date Considered	3/13/07
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/801,951
				Filing Date	March 17, 2004
				First Named Inventor	William F. DeGrado
				Art Unit	1615
				Examiner Name	To be assigned
Sheet	6	of	8	Attorney Docket Number	1694.0630003/JMC/AES

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published, etc.	T ²
YC	BA6	Sinha, S., <i>et al.</i> , "NP-1, a Rabbit α -Defensin, Prevents the Entry and Intercellular Spread of Herpes Simplex Virus Type 2," <i>Antimicrob. Agents Chemother.</i> 47:494-500, American Society for Microbiology (February 2003)	
	BB6	Steiner, H., <i>et al.</i> , "Sequence and specificity of two antibacterial proteins involved in insect immunity," <i>Nature</i> 292:246-248, Nature Publishing Group (1981)	
	BC6	Stigers, K.D., <i>et al.</i> , "Designed molecules that fold to mimic protein secondary structures," <i>Curr. Opin. Chem. Biol.</i> 3:714-723, Current Biology Ltd. (1999)	
	BD6	Tang, Y-Q., <i>et al.</i> , "A Cyclic Antimicrobial Peptide Produced in Primate Leukocytes by the Ligation of Two Truncated α -Defensins," <i>Science</i> 286:498-502, American Association for the Advancement of Science (1999)	
	BE6	Tew, G.N., <i>et al.</i> , "De novo design of biomimetic antimicrobial polymers," <i>Proc. Natl. Acad. Sci. USA</i> 99:5110-5114, National Academy of Sciences (April 2002)	
	BF6	Threlfall, E.J., <i>et al.</i> , "Increasing spectrum of resistance in multiresistant <i>Salmonella typhimurium</i> ," <i>Lancet</i> 347:1053-1054, Lancet Publishing Group (1996)	
	BG6	Tiller, J.C., <i>et al.</i> , "Designing surfaces that kill bacteria on contact," <i>Proc. Natl. Acad. Sci. USA</i> 98:5981-5985, National Academy of Sciences (2001)	
	BH6	Tossi, A., <i>et al.</i> , "Amphipathic, α -Helical Antimicrobial Peptides," <i>Biopolymers</i> 55:4-30, Wiley Interscience (2000)	
	BI6	Turpie, A.G.G., "Pharmacology of the low-molecular-weight heparins," <i>Am. Heart J.</i> 135:S329-S335, Mosby (1998)	
	BJ6	Van Ryn-McKenna, J., <i>et al.</i> , "Neutralization of Enoxaparine-Induced Bleeding by Protamine Sulfate," <i>Thromb. Haemost.</i> 63:271-274, Schattauer (1990)	

Examiner Signature		Date Considered	3/13/07
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/801,951
				Filing Date	March 17, 2004
				First Named Inventor	William F. DeGrado
				Art Unit	1615
				Examiner Name	To be assigned
Sheet	7	of	8	Attorney Docket Number	1694.0630003/JMC/AES

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published, etc.	T ²
VC	BA7	Wachinger, M., <i>et al.</i> , "Antimicrobial peptides melittin and cecropin inhibit replication of human immunodeficiency virus 1 by suppressing viral gene expression," <i>J. Gen. Virol.</i> 79:731-740, Cambridge University Press (1998)	
	BB7	Wakefield, T.W., <i>et al.</i> , "A [+18RGD] Protamine Variant for Nontoxic and Effective Reversal of Conventional Heparin and Low-Molecular-Weight Heparin Anticoagulation," <i>J. Surg. Res.</i> 63:280-286, Academic Press (1996)	
	BC7	Wong, P.C., <i>et al.</i> , "Nonpeptide Factor Xa Inhibitors: I. Studies with SF303 and SK549, a New Class of Potent Antithrombotics," <i>J. Pharmacol. Exp. Therap.</i> 292:351-357, American Society for Pharmacology and Experimental Therapeutics (2000)	
	BD7	Woo, G.L.Y., <i>et al.</i> , "Synthesis and characterization of a novel biodegradable antimicrobial polymer," <i>Biomaterials</i> 21:1235-1246, Elsevier (2000)	
	BE7	Yamaguchi, I., <i>et al.</i> , "Synthesis of polyurea rotaxanes using a cyclodextrin complex of α , ω -diamine," <i>Polym. Bull.</i> 44:247-253, Springer-Verlag (2000)	
	BF7	Zasloff, M., "Antibiotic peptides as mediators of innate immunity," <i>Curr. Opin. Immunol.</i> 4:3-7, Current Biology Ltd. (1992)	
	BG7	Zasloff, M., "Antimicrobial peptides of multicellular organisms," <i>Nature</i> 415:389-395, Nature Publishing Group (January 2002)	
	BH7	Zasloff, M., "Reconstructing one of nature's designs," <i>Trends Pharmacol. Sci.</i> 21:236-238, Elsevier (2000)	
	BI7	Zhang, L., <i>et al.</i> , "Contribution of Human α -Defensin 1, 2, and 3 to the Anti-HIV-1 Activity of CD8 Antiviral Factor," <i>Science</i> 298:995-1000, American Association for the Advancement of Science (November 2002)	
	BJ7	Zhao, C., <i>et al.</i> , "Identification of a new member of the protegrin family by cDNA cloning," <i>FEBS Lett.</i> 346:285-288, Elsevier (1994)	

Examiner Signature		Date Considered	5/13/07
--------------------	---	-----------------	---------

*EXAMINER: Initially reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/801,951
				Filing Date	March 17, 2004
				First Named Inventor	William F. DeGrado
				Art Unit	1615
				Examiner Name	To be assigned
Sheet	8	of	8	Attorney Docket Number	1694.0630003/JMC/AES

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ^o	Cite No. ¹	Include name of the author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published, etc.	T ²
4C	BA8	U.S. Patent Application entitled "Facially Amphiphilic Polyaryl and Polyarylkynyl Polymers and Oligomers and Uses Thereof," filed January 21, 2005, naming as inventors William F. DeGrado, Dahui Liu, Gregory N. Tew, and Michael L. Klein, (Attorney Docket No. 1694.0590001/JMC/AES)	
	BB		
	BC		
	BD		
	BE		
	BF		
	BG		
	BH		
	BI		
	BJ		

Examiner Signature		Date Considered	3/13/07
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.